Investigational Studies

LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject to market and other conditions, $225 million of American Depositary Shares (“ADSs”) representing ordinary shares […]

by

LONDON, Dec. 06, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 2,400,000 American Depositary Shares (“ADSs”), representing 28,800,000 ordinary […]

by

British company GW Pharma will sell more than 2 million shares on NASDAQ, which will bring in the money needed to advance its impressive pipeline even further. GW Pharma focuses on the development of therapeutics using its cannabinoid product platform for a range of diseases, including autism, epilepsy and brain cancer. Today, the company announced the […]

by

Admittedly, 2017 so far has kind of been a ho-hum year for former high-flying marijuana stock GW Pharmaceuticals (NASDAQ:GWPH). For the most part, investors have just been waiting for the next big event for the cannabinoid-focused biotech. GW Pharmaceuticals CEO Justin Gover doesn’t think they’ll have to wait much longer. Speaking at the Piper Jaffray […]

by

LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject to market and other conditions, $225 million of American Depositary Shares (“ADSs”) representing ordinary shares […]

by

LONDON, Dec. 06, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 2,400,000 American Depositary Shares (“ADSs”), representing 28,800,000 ordinary […]

by

– Epidiolex® (cannabidiol) NDA Submitted to FDA – – Conference call today at 7:30 a.m. EST –   London, UK, Carlsbad, CA, 4 Dec 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial […]

by

LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject to market and other conditions, $225 million of American Depositary Shares (“ADSs”) representing ordinary shares […]

by

– Epidiolex® (cannabidiol) NDA Submitted to FDA –– Conference call today at 7:30 a.m. EST – LONDON and CARLSBAD, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial […]

by

– Epidiolex® (cannabidiol) NDA Submitted to FDA –– Conference call today at 7:30 a.m. EST – LONDON and CARLSBAD, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial […]

by

– Epidiolex® (cannabidiol) NDA Submitted to FDA –– Conference call today at 7:30 a.m. EST – LONDON and CARLSBAD, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial […]

by

Over 20 abstracts released online today from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet syndrome and from Expanded Access Program LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, […]

by